SLC35C2

Across TCGA pan-cancer cohorts, SLC35C2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SLC35C2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where SLC35C2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC35C2 is over-expressed in tumor.

PDAC, LSCC, and HNSC are the cancer types where SLC35C2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC35C2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	All	+0.810	.002	2	view →
LSCC	Female	All	+0.229	.027	1	view →
HNSC	All	IV	+0.178	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SLC35C2–PDAC

Open the PDAC breakdown →